Evidence map›Paper›PMID 38526050›Full record

ArticleAntimicrobial agents and chemotherapy2024

Mariana Castanheira, John H Kimbrough, Jill Lindley, Timothy B Doyle, Jessica M Ewald, Helio S Sader

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Ceftazidime-avibactam resistance evolution inAntimicrobial agents and chemotherapy · 2026
    Article
  2. Antimicrobial Susceptibility ofAntibiotics (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Activity of cefiderocol againstMicrobiology spectrum · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mariana CastanheiraJMI Laboratories, North Liberty, Iowa, USA.ORCID 0000-0003-0126-1782
John H KimbroughJMI Laboratories, North Liberty, Iowa, USA.ORCID 0000-0002-0457-1543
Jill LindleyJMI Laboratories, North Liberty, Iowa, USA.
Timothy B DoyleJMI Laboratories, North Liberty, Iowa, USA.
Jessica M EwaldJMI Laboratories, North Liberty, Iowa, USA.
Helio S SaderJMI Laboratories, North Liberty, Iowa, USA.ORCID 0000-0001-7022-6644
JMI Laboratories · USJackson Laboratory · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We subjected seven

Indexed as

Anti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-LactamsCeftazidimeMeropenemMicrobial Sensitivity TestsPiperacillin, Tazobactam Drug CombinationPseudomonas aeruginosaTazobactamCefepimeCephalosporinsDrug CombinationsDrug Resistance, Multiple, BacterialHumansPiperacillinAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-LactamsCefepimeCeftazidimeceftolozane, tazobactam drug combinationCephalosporinsDrug CombinationsMeropenemPiperacillinPiperacillin, Tazobactam Drug CombinationTazobactammutationsP. aeruginosaβ-lactams

Identifiers

PMID38526050
PMCPMC11064483
OpenAlexW4393157556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.